CYP3A-dependent drug metabolism is reduced in bacterial inflammation in mice

British Journal of Pharmacology

Volumn 166, Issue 7, 2012, Pages 2176-2187

  Gandhi, A S ^a   Guo, T ^a   Shah, P ^a   Moorthy, B ^b   Chow, D S L ^a   Hu, M ^a   Ghose, R ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

inflammation; lipoteichoic acid; LPS; midazolam; pharmacokinetics and pharmacodynamics

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; ALPHA HYDROXYMIDAZOLAM GLUCURONIDE; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; CYTOCHROME P450 3A; MIDAZOLAM; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG METABOLISM; ENZYME ACTIVITY; INFLAMMATION; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLIC REGULATION; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SLEEP TIME; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84863643559     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.01933.x     Document Type: Article

References (57)

1. Alexander SPH, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th Edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
2. Barclay TB, Peters JM, Sewer MB, Ferrari L, Gonzalez FJ, Morgan ET, (1999). Modulation of cytochrome P-450 gene expression in endotoxemic mice is tissue specific and peroxisome proliferator-activated receptor-alpha dependent. J Pharmacol Exp Ther 290: 1250-1257.
3. Bauer TM, Ritz R, Haberthur C, Ha HR, Hunkeler W, Sleight AJ, et al,. (1995). Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet 346: 145-147.
4. Bornemann LD, Min BH, Crews T, Rees MM, Blumenthal HP, Colburn WA, et al,. (1985). Dose dependent pharmacokinetics of midazolam. Eur J Clin Pharmacol 29: 91-95.
5. Chaluvadi MR, Kinloch RD, Nyagode BA, Richardson TA, Raynor MJ, Sherman M, et al,. (2009). Regulation of hepatic cytochrome P450 expression in mice with intestinal or systemic infections of citrobacter rodentium. Drug Metab Dispos 37: 366-374.
6. Chen J, Lin H, Hu M, (2003). Metabolism of flavonoids via enteric recycling: role of intestinal disposition. J Pharmacol Exp Ther 304: 1228-1235.
7. Driessen JJ, Vree TB, Guelen PJ, (1991). The effects of acute changes in renal function on the pharmacokinetics of midazolam during long-term infusion in ICU patients. Acta Anaesthesiol Belg 42: 149-155.
8. Fitzgerald KA, Palsson-McDermott EM, Bowie AG, Jefferies CA, Mansell AS, Brady G, et al,. (2001). Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature 413: 78-83.
9. Floyd MD, Gervasini G, Masica AL, Mayo G, George AL, Jr, Bhat K, et al,. (2003). Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 13: 595-606.
10. Gandhi A, Guo T, Ghose R, (2011). Role of c-Jun N-terminal kinase (JNK) in regulating tumor necrosis factor-alpha (TNF-alpha) mediated increase of acetaminophen (APAP) and chlorpromazine (CPZ) toxicity in murine hepatocytes. J Toxicol Sci 35: 163-173.
11. Ghose R, White D, Guo T, Vallejo J, Karpen SJ, (2008). Regulation of hepatic drug-metabolizing enzyme genes by Toll-like receptor 4 signaling is independent of Toll-interleukin 1 receptor domain-containing adaptor protein. Drug Metab Dispos 36: 95-101.
12. Ghose R, Guo T, Haque N, (2009). Regulation of gene expression of hepatic drug metabolizing enzymes and transporters by the Toll-like receptor 2 ligand, lipoteichoic acid. Arch Biochem Biophys 481: 123-130.
13. Ghose R, Guo T, Vallejo JG, Gandhi A, (2011). Differential role of Toll-interleukin 1 receptor domain-containing adaptor protein in Toll-like receptor 2-mediated regulation of gene expression of hepatic cytokines and drug-metabolizing enzymes. Drug Metab Dispos 39: 874-881.
14. Giannini E, Fasoli A, Botta F, Romagnoli P, Malfatti F, Chiarbonello B, et al,. (2003). Helicobacter pylori infection is associated with greater impairment of cytochrome P-450 liver metabolic activity in anti-HCV positive cirrhotic patients. Dig Dis Sci 48: 802-808.
15. Gorski JC, Vannaprasaht S, Hamman MA, Ambrosius WT, Bruce MA, Haehner-Daniels B, et al,. (2003). The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther 74: 275-287.
16. Greenblatt DJ, von Moltke LL, Harmatz JS, Chen G, Weemhoff JL, Jen C, et al,. (2003). Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. Clin Pharmacol Ther 74: 121-129.
17. Guengerich FP, (1999). Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39: 1-17.
18. Hartmann G, Vassileva V, Piquette-Miller M, (2005). Impact of endotoxin-induced changes in P-glycoprotein expression on disposition of doxorubicin in mice. Drug Metab Dispos 33: 820-828.
19. He P, Court MH, Greenblatt DJ, Von Moltke LL, (2005). Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clin Pharmacol Ther 77: 373-387.
20. He P, Court MH, Greenblatt DJ, von Moltke LL, (2006). Factors influencing midazolam hydroxylation activity in human liver microsomes. Drug Metab Dispos 34: 1198-1207.
21. Heizmann P, Eckert M, Ziegler WH, (1983). Pharmacokinetics and bioavailability of midazolam in man. Br J Clin Pharmacol 16 (Suppl. 1): 43S-49S.
22. Hoogerwerf JJ, de Vos AF, Bresser P, van der Zee JS, Pater JM, de Boer A, et al,. (2008). Lung inflammation induced by lipoteichoic acid or lipopolysaccharide in humans. Am J Respir Crit Care Med 178: 34-41.
23. Horng T, Barton GM, Medzhitov R, (2001). TIRAP: an adapter molecule in the Toll signaling pathway. Nat Immunol 2: 835-841.
24. Horng T, Barton GM, Flavell RA, Medzhitov R, (2002). The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature 420: 329-333.
25. Kotegawa T, Laurijssens BE, Von Moltke LL, Cotreau MM, Perloff MD, Venkatakrishnan K, et al,. (2002). In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. J Pharmacol Exp Ther 302: 1228-1237.
26. Mandema JW, Tuk B, van Steveninck AL, Breimer DD, Cohen AF, Danhof M, (1992). Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther 51: 715-728.
27. Marshall T, Shult P, Busse WW, (1988). Release of lysosomal enzyme beta-glucuronidase from isolated human eosinophils. J Allergy Clin Immunol 82: 550-555.
28. Martin GS, Mannino DM, Eaton S, Moss M, (2003). The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348: 1546-1554.
29. Matuskova Z, Tunkova A, Anzenbacherova E, Zidek Z, Tlaskalova-Hogenova H, Anzenbacher P, (2009). Influence of probiotics on rat liver biotransformation enzymes. Neuro Endocrinol Lett 30 (Suppl. 1): 41-45.
30. McGrath J, Drummond G, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
31. von Moltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS, et al,. (1996). Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol 36: 783-791.
32. Monshouwer M, Witkamp RF, Nijmeijer SM, Van Leengoed LA, Vernooy HC, Verheijden JH, et al,. (1996). A lipopolysaccharide-induced acute phase response in the pig is associated with a decrease in hepatic cytochrome P450-mediated drug metabolism. J Vet Pharmacol Ther 19: 382-388.
33. Morgan ET, (1989). Suppression of constitutive cytochrome P-450 gene expression in livers of rats undergoing an acute phase response to endotoxin. Mol Pharmacol 36: 699-707.
34. Morgan ET, (1997). Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev 29: 1129-1188.
35. Palkama VJ, Ahonen J, Neuvonen PJ, Olkkola KT, (1999). Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. Clin Pharmacol Ther 66: 33-39.
36. Perloff MD, von Moltke LL, Court MH, Kotegawa T, Shader RI, Greenblatt DJ, (2000). Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. J Pharmacol Exp Ther 292: 618-628.
37. Perloff MD, Von Moltke LL, Greenblatt DJ, (2003). Differential metabolism of midazolam in mouse liver and intestine microsomes: a comparison of cytochrome P450 activity and expression. Xenobiotica 33: 365-377.
38. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, et al,. (2001). Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299: 620-628.
39. Reed MD, Rodarte A, Blumer JL, Khoo KC, Akbari B, Pou S, et al,. (2001). The single-dose pharmacokinetics of midazolam and its primary metabolite in pediatric patients after oral and intravenous administration. J Clin Pharmacol 41: 1359-1369.
40. Renton KW, Nicholson TE, (2000). Hepatic and central nervous system cytochrome P450 are down-regulated during lipopolysaccharide-evoked localized inflammation in brain. J Pharmacol Exp Ther 294: 524-530.
41. Richardson TA, Sherman M, Kalman D, Morgan ET, (2006). Expression of UDP-glucuronosyltransferase isoform mRNAs during inflammation and infection in mouse liver and kidney. Drug Metab Dispos 34: 351-353.
42. Ruot B, Breuille D, Rambourdin F, Bayle G, Capitan P, Obled C, (2000). Synthesis rate of plasma albumin is a good indicator of liver albumin synthesis in sepsis. Am J Physiol Endocrinol Metab 279: E244-E251.
43. Sewer MB, Koop DR, Morgan ET, (1996). Endotoxemia in rats is associated with induction of the P4504A subfamily and suppression of several other forms of cytochrome P450. Drug Metab Dispos 24: 401-407.
44. Sewer MB, Koop DR, Morgan ET, (1997). Differential inductive and suppressive effects of endotoxin and particulate irritants on hepatic and renal cytochrome P-450 expression. J Pharmacol Exp Ther 280: 1445-1454.
45. Shedlofsky SI, Israel BC, McClain CJ, Hill DB, Blouin RA, (1994). Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism. J Clin Invest 94: 2209-2214.
46. Shimada T, Gillam EM, Sandhu P, Guo Z, Tukey RH, Guengerich FP, (1994). Activation of procarcinogens by human cytochrome P450 enzymes expressed in Escherichia coli. Simplified bacterial systems for genotoxicity assays. Carcinogenesis 15: 2523-2529.
47. Shimoi K, Saka N, Nozawa R, Sato M, Amano I, Nakayama T, et al,. (2001). Deglucuronidation of a flavonoid, luteolin monoglucuronide, during inflammation. Drug Metab Dispos 29: 1521-1524.
48. Siewert E, Bort R, Kluge R, Heinrich PC, Castell J, Jover R, (2000). Hepatic cytochrome P450 down-regulation during aseptic inflammation in the mouse is interleukin 6 dependent. Hepatology 32: 49-55.
49. Sriskandan S, Cohen J, (1999). Gram-positive sepsis. Mechanisms and differences from gram-negative sepsis. Infect Dis Clin North Am 13: 397-412.
50. Swart EL, de Jongh J, Zuideveld KP, Danhof M, Thijs LG, Strack van Schijndel RJ, (2005). Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. Am J Kidney Dis 45: 360-371.
51. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, et al,. (1994). Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 271: 549-556.
52. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, et al,. (1996). Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 59: 491-502.
53. Wang XY, Li WQ, Lu J, Li N, Li JS, (2005). Mechanism of reduction of albumin expression induced by lipopolysaccharide in rat hepatocytes. Chin Med J (Engl) 118: 1695-1702.
54. Warrington JS, Poku JW, von Moltke LL, Shader RI, Harmatz JS, Greenblatt DJ, (2000). Effects of age on in vitro midazolam biotransformation in male CD-1 mouse liver microsomes. J Pharmacol Exp Ther 292: 1024-1031.
55. van Waterschoot RA, van Herwaarden AE, Lagas JS, Sparidans RW, Wagenaar E, van der Kruijssen CM, et al,. (2008). Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes. Mol Pharmacol 73: 1029-1036.
56. Zhu B, Bush D, Doss GA, Vincent S, Franklin RB, Xu S, (2008). Characterization of 1'-hydroxymidazolam glucuronidation in human liver microsomes. Drug Metab Dispos 36: 331-338.
57. Ziegler WH, Schalch E, Leishman B, Eckert M, (1983). Comparison of the effects of intravenously administered midazolam, triazolam and their hydroxy metabolites. Br J Clin Pharmacol 16 (Suppl. 1): 63S-69S.